[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Chiba University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":89},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,58],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":33,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":46,"lastUpdatePostDateStruct":47,"startDateStruct":50,"completionDateStruct":52,"leadSponsor":54,"locationsCount":57},"100597682","cities-for-better-health-childhood-obesity-prevention-initiative-in-japan-100597682",false,"NCT07061665","Cities for Better Health Childhood Obesity Prevention Initiative in JAPAN","CBH COPI JAPAN","Inclusion Criteria:\n\n* Children aged 6 to 12 years who are currently enrolled in one of the public elementary schools located within the 22 participating Junior High School District clusters in Chiba City.\n* The parent or legal guardian of each child must provide written informed consent prior to participation.\n* Parents or legal guardians must have sufficient Japanese language proficiency to understand study procedures, complete questionnaires, and provide accurate information during the study.\n* Children must be physically and cognitively capable of participating in school- and community-based activities involved in the intervention.\n* Participants must not have any medical conditions that would preclude safe participation in routine physical activities promoted by the intervention.\n\nExclusion Criteria:\n\n* Children whose parents or legal guardians fail to provide complete informed consent.\n* Families who withdraw consent at any point during the study period.\n* Children who independently express refusal to participate, even with parental consent.\n* Children with serious physical, psychological, or developmental disorders that prevent them from participating safely in the program's activities.\n* Families planning to relocate outside of Chiba City during the study period, making follow-up assessment infeasible.",true,"ALL","6 Years","12 Years",{"count":21,"type":22},2200,"ESTIMATED","INTERVENTIONAL",[25],"NA","The goal of this interventional study is to prevent childhood obesity in children aged 6-12 years in Chiba City, Japan. The main questions it aims to answer are:\n\n* Does the multi-component intervention for environments around children reduce the BMI z-score of children aged 6-12 years after one and two years?\n* Does the multi-component intervention for environments around children improve the health-related quality of life (assessed by KIDSCREEN-10) of children aged 6-12 years after one and two years?\n\nResearchers will compare school clusters receiving the intervention to control clusters to see if the intervention package promotes healthy eating, increases physical activity, improves health-related quality of life, and reduces obesity prevalence.\n\nParticipants will:\n\n* Attend elementary schools within participating clusters (either the intervention or control group).\n* Have baseline data collected, with follow-up assessments after one year and two years.\n* Potentially participate in school-based programs (nutrition education, physical activity promotion) and community-based initiatives (park activation, supermarkets) if in an intervention cluster.\n* Have their physical activity and dietary behavior assessed through self-report questionnaires.",[28,29,30,31,32],"Quality of Life (QOL)","Nutrition","Physical Activity","Obesity","Childhood Obesity",[34,35,36,37,38,39,40,41,42,43,44],"BMI","Childhood obesity","Japan","Chiba city","physical activity","nutrition","health equity","community intervention","randomized controlled trial","KIDSCREEN-10","Diet Quality Questionnaire","NOT_YET_RECRUITING","2025-07-02",{"date":48,"type":49},"2025-07-11","ACTUAL",{"date":51,"type":22},"2025-07",{"date":53,"type":22},"2027-09",{"name":55,"class":56},"Chiba University","OTHER",1,{"id":59,"slug":60,"hasResults":11,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":64,"eligibilityCriteria":65,"healthyVolunteers":11,"sex":17,"minAge":66,"maxAge":4,"enrollmentInfo":67,"targetDuration":4,"studyType":23,"phases":69,"briefSummary":71,"conditions":72,"keywords":74,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},"100563094","phase-4-avacopan-vs-reduced-dose-glucocorticoids-in-anca-associated-vasculitis-100563094","NCT06611696","Avacopan vs Reduced-dose Glucocorticoids in ANCA-associated Vasculitis","Avacopan With Short-term Reduced-dose Glucocorticoids vs Reduced-dose Glucocorticoids Added to Rituximab on Remission Induction in ANCA-associated Vasculitis","ARRIA","Inclusion Criteria:\n\n1. Provision of written informed consent by a patient or a surrogate decision maker\n2. Age=\\>18 years\n3. New clinical diagnosis of ANCA-associated vasculitis (granulomatosis with polyangiitis, microscopic polyangiitis) consistent with the 2012 Chapel Hill consensus definitions and 2022 EULAR\u002FACR classification criteria\n4. Positive test by ELISA, CLEIA or FEIA for proteinase 3-ANCA or myeloperoxidase-ANCA\n\nExclusion Criteria:\n\n1. Prior treatment for ANCA-associated vasculitis before trial entry\n2. ANCA-associated vasculitis related glomerulonephritis (eGFR less than 15ml\u002Fmin) or alveolar hemorrhage (oxygen inhalation more than 2L\u002Fmin)\n3. Presence of another multisystem autoimmune disease\n4. Known infection with HIV; a past or current history of hepatitis B virus or hepatitis C virus infection\n5. Desire to bear children, pregnancy or lactating\n6. History of malignancy within the past 5 years or any evidence of persistent malignancy\n7. Ongoing or recent (last 1 year) evidence of active tuberculosis\n8. History of severe allergy or anaphylaxis to monoclonal antibody therapy\n9. Any concomitant condition anticipated to likely require oral systemic glucocorticoids, immunosuppressants, biologics, plasma exchange or IVIg\n10. Any biological B cell depleting agent (such as rituximab or belimumab)-use within the past 6 months\n11. Past history of medication of avacopan\n12. Patients can not take avacopan and prednisolone orally\n13. Other conditions, in the investigator\\'s opinion, inappropriate for the trial entry","18 Years",{"count":68,"type":22},160,[70],"PHASE4","The goal of this clinical trial is to learn if avacopan in combination with short-term (4 weeks) reduced-dose glucocorticoid and rituximab works to treat patients with newly-onset ANCA-associated vasculitis. It will also learn about the long-term safety of avacopan. The main questions it aims to answer are:\n\nIs avacopan in combination with short-term reduced-dose glucocorticoid and rituximab as effective as the combination of 20 week reduced-dose glucocorticoid and rituximab in the proportion of the patients achieving remission? Does avacopan lower the relapse rate compared to the 6 monthly rituximab maintenance therapy? What medical problems do participants have when taking long-term avacopan?\n\nParticipants will:\n\nBe treated with avacopan in combination with short-term (until 4 weeks) reduced-dose glucocorticoid and rituximab (at 0 week) or reduced-dose glucocorticoid (until 20 weeks) and rituximab (at 0, 26, 52 and 78 weeks).\n\nBe assessed at 0, 4, 8, 16, 26, 52, 78 and 104 weeks regarding disease status (remission\u002Frelapse), disease activity by Birmingham Vasculitis Activity Score ver3, disease damage by Vasculitis Damage Index and adverse events.\n\nThe primary endpoint is remission rates at 26 weeks.",[73],"ANCA Associated Vasculitis (AAV)",[75,76,77,78],"microscopic polyangiitis","granulomatosis with polyangiitis","avacopan","ANCA-associated vasculitis","RECRUITING","2025-05-01",{"date":82,"type":49},"2025-05-04",{"date":84,"type":49},"2024-11-15",{"date":86,"type":22},"2028-09-30",{"name":55,"class":56},22,""]